石四药集团：已取得中国国家药品监督管理局有关吲哚布芬片的药品生产注册批件

Core Viewpoint - The company has obtained the production registration approval for Indobufen Tablets (0.2g) from the National Medical Products Administration of China, which is classified as a Class 3 chemical drug and is considered to have passed the consistency evaluation [1] Group 1 - The Indobufen Tablets are primarily used for the treatment of ischemic cardiovascular diseases caused by arteriosclerosis, ischemic cerebrovascular diseases, and venous thrombosis [1] - The tablets can also be used to prevent thrombosis during hemodialysis [1]